Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214759 · ClinicalTrials.gov registry record · Phase 4
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
NCT01214759: Completed Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
NCT01214759 is a Phase 4 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 103 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01214759, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of the combination of truvada and raltegravir given for 28 days for the prevention of HIV infection.
Primary Outcome
This measure assesses whether the combination of Truvada and Raltegravir prevents the acquisition of HIV at six months among HIV-negative people who have been exposed to HIV.
Interventions
- DRUG Truvada
- DRUG Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-08 |
| Phase | Phase 4 |
What the finished NCT01214759 record still lists
NCT01214759 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Truvada is the first listed.
NCT01214759 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01214759 about?
NCT01214759 is a clinical study titled "Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)". This study will evaluate the safety and tolerability of the combination of truvada and raltegravir given for 28 days for the prevention of HIV infection.
What is the current status of trial NCT01214759?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2011-05. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01214759?
The interventions under investigation include: Truvada (DRUG), Raltegravir (DRUG).
Who is sponsoring clinical trial NCT01214759?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01214759's enrollment target sits among peer trials
103 760th of 2000 higher than 1,237 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia